As the preceding results showed that LPCAT1-mediated gefitinib resistance of PC-9R cells is closely associated with the EGFR/PI3K/AKT pathway, we next verified this result by establishing a tumor-bearing mouse model. This evidence concerns the gene LPCAT1 and neoplasm.